Skip to main content

Table 4 Significantly different values in NK cell subsets in controls (Ctrl) and recurrent SCCHN patients

From: Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)

%

Ctrl

t0

t1

t2

t5

CD56bright/CD16−

NK cells

1.83 ± 1.14

0.92 ± 0.7*

0.75 ± 0.63*

2.07 ± 1.52

1.6 ± 1.52

CD56bright/CD16+

NK cells

2.52 ± 1.34

2.88 ± 1.85

1.47 ± 0.7*

5.76 ± 4.85

1.54 ± 1.32

CD56dim/CD16−

NK cells

2.8 ± 1.8

10.19 ± 11.85

6.08 ± 5.3

4.3 ± 3.97

2.25 ± 2.05

CD56dim/CD16+

NK cells

87.27 ± 5.97

81.4 ± 13.9

88.23 ± 7.52

84.78 ± 11.56

92.88 ± 4.26*

CD56−/CD16+

NK cells

0 ± 0

0 ± 0

0 ± 0

0 ± 0

0 ± 0

  1. The significance is between the two underlined values. E.g. significance in CD56bright/CD16- NK cells between t0 and t1 is *p<=0.05
  2. Composition of NK cell subsets (CD56/CD16) in % (mean value ± standard deviation) in healthy controls (Ctrl, n = 22) and recurrent patients (n = 9) before (t0), after application of 20–30 Gy (t1), 3 months (t2) after RCT and at time of locoregional recurrence (t5, 3–15 months after t0). Significantly different values (Ctrl vs. t0, t1; t0 vs. t1; Ctrl vs. t5) are indicated in bold with an asterisk (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001)
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us